With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

Novo Nordisk trades at a significant discount to Eli Lilly, offering nearly 38% upside. Click here to find out why NVO stock is a Buy.

Ongoing patent battle between Novo Nordisk and Dr Reddy’s Laboratories over semaglutide export to multiple countries.

The runaway success of GLP-1 drugs made Novo Nordisk, a Danish drugmaker, the top company in Europe by market cap. These medications, injected into the body, mimic a hormone that regulates blood ...

A federal district court in Delaware ruled that Viatris’ product, currently awaiting approval from the US Food and Drug Administration (FDA), does not infringe on Novo Nordisk’s patent for the ...

You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy. This site is protected by ...

Ozempic, a type 2 diabetes treatment, presents investment opportunities via Novo Nordisk stock. Projected GLP-1 market growth to almost $160 billion by early the 2030s indicates long-term sector ...

Novo Nordisk’s arch-rival in the obesity market is Eli Lilly LLY. NVO’s Ozempic and Wegovy face strong competition from Lilly’s tirzepatide medicines, Mounjaro (T2D) and Wegovy (obesity).

Novo Nordisk’s annual report contains an interesting footnote on its key drug, Ozempic, which last year accounted for $19 billion of sales worldwide.

Maker of Ozempic and Wegovy faces grilling over high cost of weight loss drugs In a statement Monday, Novo Nordisk defended its pricing structure.

Novo Nordisk rode Ozempic's success to becoming Europe's top company. Now it's faltering and its CEO is out. Provided by Dow Jones May 16, 2025, 1:38:00 PM. By Steve Goldstein .